Drug intelligence / Profile preview

gamma-aminobutyric acid

Development stage
Phase 4
Lead developer
Alfresa
Modality
Small Molecules
Administration
Oral
01

Overview

Gamma-aminobutyric acid (GABA) is a non-proteinogenic amino acid that serves as the chief inhibitory neurotransmitter in the mature mammalian central nervous system. It is synthesized primarily from glutamate via the enzyme glutamate decarboxylase, with pyridoxal phosphate as a cofactor. GABA acts at inhibitory synapses by binding to specific transmembrane receptors on neurons, leading to the opening of ion channels and resulting in hyperpolarization of neuronal membranes. This action reduces neuronal excitability and regulates muscle tone. There are three main classes of GABA receptors: GABAA and GABAC (ionotropic), which are ligand-gated ion channels, and GABAB (metabotropic), which is a G protein-coupled receptor[2][3][5]. While it is an amino acid, it is not incorporated into proteins nor classified among standard dietary amino acids[8]. Exogenous administration of GABA has been explored for effects such as improving sleep quality and reducing blood pressure; however, its ability to cross the blood-brain barrier remains under investigation[2][8].

Brand names
PharmaGABA
Other names
4-Aminobutanoic acidγ-Aminobutyric acidgamma-amino-n-butyric acidaminobutyric acidGammalone
02

Targets

GABRR (GABA-A receptor subunit rho)GABA-B (Gamma-aminobutyric acid receptor type B)

Beyond the preview

Go deeper on gamma-aminobutyric acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gamma-aminobutyric acid.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call